{"schema_version":"alpha-governance-record-v2","alpha_id":"alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce","ontology_version":"alpha-governance-ontology-v1","as_of":"2026-10-17T11:11:48.633766+00:00","published_at":"2026-10-17T04:46:51.162298+00:00","section":"events","data":{"state":"PUBLISHED","derivation_version":"alpha-governance-event-derivation-v2","events":[{"event_id":"alpha:event:transition:jjgkap1w8yplh","event_type":"CEO_CHANGED","effective_at":"2026-04-07","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:jacqueline-e-shea-ph-d","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:13"],"evidence_ids":["alpha:projection-evidence:document:8f1294f7e46937438027b3cfe480ffb2c6ed0135bd93cc79e537c23f01fedff9"],"summary":"Jacqueline E. Shea, Ph.D. executive of INOVIO PHARMACEUTICALS, INC., effective 2026-04-07.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:31h1qz8blpmx","event_type":"EXECUTIVE_APPOINTED","effective_at":"2026-04-07","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:laurent-m-humeau-ph-d","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:14"],"evidence_ids":["alpha:projection-evidence:document:4b6e35f2d5f0e990b07174a46dcbe4b9422ef8f6ae83cd57bc85bb1eca11cb36"],"summary":"Laurent M. Humeau, Ph.D. executive of INOVIO PHARMACEUTICALS, INC., effective 2026-04-07.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:12zps551xx7ai7","event_type":"EXECUTIVE_APPOINTED","effective_at":"2026-04-07","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:michael-sumner-m-d","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:15"],"evidence_ids":["alpha:projection-evidence:document:5a31bde93476f8a37d8a1cb66aac2b1b2e3aa3a1855d7f789b5dcbbd6d35fe90"],"summary":"Michael Sumner, M.D. executive of INOVIO PHARMACEUTICALS, INC., effective 2026-04-07.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1qaxfobg7zuk","event_type":"CFO_CHANGED","effective_at":"2026-04-07","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:peter-d-kies","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:16"],"evidence_ids":["alpha:projection-evidence:document:c24c5ae9b36a12f3ac9677930fba7288f90d4d4134ae372ad980e33a71422925"],"summary":"Peter D. Kies executive of INOVIO PHARMACEUTICALS, INC., effective 2026-04-07.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1qsnms11h4oo3","event_type":"DIRECTOR_APPOINTED","effective_at":"2022-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:jacqueline-e-shea-ph-d","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:7"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"Jacqueline E. Shea, Ph.D. seat on INOVIO PHARMACEUTICALS, INC., effective 2022-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1j092vcz5q5xa","event_type":"DIRECTOR_APPOINTED","effective_at":"2021-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:roger-d-dansey-m-d","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:10"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"Roger D. Dansey, M.D. seat on INOVIO PHARMACEUTICALS, INC., effective 2021-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:f6bkv01ufsdvy","event_type":"DIRECTOR_APPOINTED","effective_at":"2020-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:jay-p-shepard","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"Jay P. Shepard seat on INOVIO PHARMACEUTICALS, INC., effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:kuafxwd8633q","event_type":"COMMITTEE_CREATED","effective_at":"2020-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:committee:inovio-pharmaceuticals-inc:audit-nominating-and-governance","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"Audit; Nominating and Governance committee of INOVIO PHARMACEUTICALS, INC., effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:2cjkvilnfypu","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2020-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:jay-p-shepard","alpha:committee:inovio-pharmaceuticals-inc:audit-nominating-and-governance"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"Jay P. Shepard member of Audit; Nominating and Governance, effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1k2dyqh3fpqtp","event_type":"DIRECTOR_APPOINTED","effective_at":"2019-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:ann-c-miller-m-d","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:5"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"Ann C. Miller, M.D. seat on INOVIO PHARMACEUTICALS, INC., effective 2019-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:90siz1104ua1t","event_type":"DIRECTOR_APPOINTED","effective_at":"2019-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:lota-s-zoth","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:9"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"Lota S. Zoth seat on INOVIO PHARMACEUTICALS, INC., effective 2019-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1vqabz710wblql","event_type":"COMMITTEE_CREATED","effective_at":"2019-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:committee:inovio-pharmaceuticals-inc:audit-chair-compensation","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:9"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"Audit · Chair; Compensation committee of INOVIO PHARMACEUTICALS, INC., effective 2019-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1lsp8ksfnz7xa","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2019-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:lota-s-zoth","alpha:committee:inovio-pharmaceuticals-inc:audit-chair-compensation"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:9"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"Lota S. Zoth member of Audit · Chair; Compensation, effective 2019-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:alm7zl1j50rvh","event_type":"DIRECTOR_APPOINTED","effective_at":"2017-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:wendy-l-yarno","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:12"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"Wendy L. Yarno seat on INOVIO PHARMACEUTICALS, INC., effective 2017-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1p2s8rz9zrxip","event_type":"COMMITTEE_CREATED","effective_at":"2017-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:committee:inovio-pharmaceuticals-inc:compensation-chair-nominating-and-governance","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:12"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"Compensation · Chair; Nominating and Governance committee of INOVIO PHARMACEUTICALS, INC., effective 2017-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:qk8zs2457gek","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2017-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:wendy-l-yarno","alpha:committee:inovio-pharmaceuticals-inc:compensation-chair-nominating-and-governance"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:12"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"Wendy L. Yarno member of Compensation · Chair; Nominating and Governance, effective 2017-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:omwyj11c4dhdt","event_type":"DIRECTOR_APPOINTED","effective_at":"2016-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:david-b-weiner-ph-d","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:6"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"David B. Weiner, Ph.D. seat on INOVIO PHARMACEUTICALS, INC., effective 2016-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:7fbjuf44sryr","event_type":"DIRECTOR_APPOINTED","effective_at":"2003-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:simon-x-benito","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:11"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"Simon X. Benito seat on INOVIO PHARMACEUTICALS, INC., effective 2003-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:by13uvx31ykj","event_type":"COMMITTEE_CREATED","effective_at":"2003-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:committee:inovio-pharmaceuticals-inc:audit-compensation-nominating-and-governance-chair","alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:11"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"Audit; Compensation; Nominating and Governance · Chair committee of INOVIO PHARMACEUTICALS, INC., effective 2003-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:13roby0xfu5ki","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2003-01-01","detected_at":"2026-10-17T04:46:51.162298+00:00","subject_ids":["alpha:person:simon-x-benito","alpha:committee:inovio-pharmaceuticals-inc:audit-compensation-nominating-and-governance-chair"],"caused_claim_ids":["alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:11"],"evidence_ids":["alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588"],"summary":"Simon X. Benito member of Audit; Compensation; Nominating and Governance · Chair, effective 2003-01-01.","derivation":"temporal_relationship_change"}]},"claims":[{"id":"alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:5","subject_id":"alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:ann-c-miller-m-d","object_label":"Ann C. Miller, M.D.","object_source_name_forms":[],"value":"Ann C. Miller, M.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:ann-c-miller-m-d","name":"Ann C. Miller, M.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2019-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2019-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:51.162298+00:00","sources":[{"id":"alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"INOVIO PHARMACEUTICALS, INC. DEF 14A 2026-04-07","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07","retrieved_at":"2026-04-24T23:51:00.991+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-07","effective_from":"2019-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:51.162298+00:00","reviewed_at":"2026-10-17T04:46:51.162298+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:6","subject_id":"alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:david-b-weiner-ph-d","object_label":"David B. Weiner, Ph.D.","object_source_name_forms":[],"value":"David B. Weiner, Ph.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:david-b-weiner-ph-d","name":"David B. Weiner, Ph.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2016-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2016-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:51.162298+00:00","sources":[{"id":"alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"INOVIO PHARMACEUTICALS, INC. DEF 14A 2026-04-07","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07","retrieved_at":"2026-04-24T23:51:00.991+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-07","effective_from":"2016-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:51.162298+00:00","reviewed_at":"2026-10-17T04:46:51.162298+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:7","subject_id":"alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:jacqueline-e-shea-ph-d","object_label":"Jacqueline E. Shea, Ph.D.","object_source_name_forms":[],"value":"Jacqueline E. Shea, Ph.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:jacqueline-e-shea-ph-d","name":"Jacqueline E. Shea, Ph.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2022-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2022-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:51.162298+00:00","sources":[{"id":"alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"INOVIO PHARMACEUTICALS, INC. DEF 14A 2026-04-07","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07","retrieved_at":"2026-04-24T23:51:00.991+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-07","effective_from":"2022-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:51.162298+00:00","reviewed_at":"2026-10-17T04:46:51.162298+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:8","subject_id":"alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:jay-p-shepard","object_label":"Jay P. Shepard","object_source_name_forms":[],"value":"Jay P. Shepard: Director, Audit; Nominating and Governance","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:jay-p-shepard","name":"Jay P. Shepard"},"title":"Director","role_category":"director","committee":"Audit; Nominating and Governance","is_board_chair":false,"is_independent":true,"start_date":"2020-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2020-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:51.162298+00:00","sources":[{"id":"alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"INOVIO PHARMACEUTICALS, INC. DEF 14A 2026-04-07","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07","retrieved_at":"2026-04-24T23:51:00.991+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-07","effective_from":"2020-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:51.162298+00:00","reviewed_at":"2026-10-17T04:46:51.162298+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:9","subject_id":"alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:lota-s-zoth","object_label":"Lota S. Zoth","object_source_name_forms":[],"value":"Lota S. Zoth: Director, Audit · Chair; Compensation","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:lota-s-zoth","name":"Lota S. Zoth"},"title":"Director","role_category":"director","committee":"Audit · Chair; Compensation","is_board_chair":false,"is_independent":true,"start_date":"2019-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2019-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:51.162298+00:00","sources":[{"id":"alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"INOVIO PHARMACEUTICALS, INC. DEF 14A 2026-04-07","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07","retrieved_at":"2026-04-24T23:51:00.991+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-07","effective_from":"2019-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:51.162298+00:00","reviewed_at":"2026-10-17T04:46:51.162298+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:10","subject_id":"alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:roger-d-dansey-m-d","object_label":"Roger D. Dansey, M.D.","object_source_name_forms":[],"value":"Roger D. Dansey, M.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:roger-d-dansey-m-d","name":"Roger D. Dansey, M.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:51.162298+00:00","sources":[{"id":"alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"INOVIO PHARMACEUTICALS, INC. DEF 14A 2026-04-07","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07","retrieved_at":"2026-04-24T23:51:00.991+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-07","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:51.162298+00:00","reviewed_at":"2026-10-17T04:46:51.162298+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:11","subject_id":"alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:simon-x-benito","object_label":"Simon X. Benito","object_source_name_forms":[],"value":"Simon X. Benito: Director, Audit; Compensation; Nominating and Governance · Chair","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:simon-x-benito","name":"Simon X. Benito"},"title":"Director","role_category":"director","committee":"Audit; Compensation; Nominating and Governance · Chair","is_board_chair":false,"is_independent":true,"start_date":"2003-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2003-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:51.162298+00:00","sources":[{"id":"alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"INOVIO PHARMACEUTICALS, INC. DEF 14A 2026-04-07","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07","retrieved_at":"2026-04-24T23:51:00.991+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-07","effective_from":"2003-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:51.162298+00:00","reviewed_at":"2026-10-17T04:46:51.162298+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:12","subject_id":"alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:wendy-l-yarno","object_label":"Wendy L. Yarno","object_source_name_forms":[],"value":"Wendy L. Yarno: Director, Compensation · Chair; Nominating and Governance","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:wendy-l-yarno","name":"Wendy L. Yarno"},"title":"Director","role_category":"director","committee":"Compensation · Chair; Nominating and Governance","is_board_chair":false,"is_independent":true,"start_date":"2017-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2017-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:51.162298+00:00","sources":[{"id":"alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"INOVIO PHARMACEUTICALS, INC. DEF 14A 2026-04-07","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07","retrieved_at":"2026-04-24T23:51:00.991+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-07","effective_from":"2017-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:51.162298+00:00","reviewed_at":"2026-10-17T04:46:51.162298+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:13","subject_id":"alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:jacqueline-e-shea-ph-d","object_label":"Jacqueline E. Shea, Ph.D.","object_source_name_forms":[],"value":"Jacqueline E. Shea, Ph.D.: President, Chief Executive Officer and Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:jacqueline-e-shea-ph-d","name":"Jacqueline E. Shea, Ph.D."},"title":"President, Chief Executive Officer and Director","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-07","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-07","valid_to":null,"recorded_at":"2026-10-17T04:46:51.162298+00:00","sources":[{"id":"alpha:projection-evidence:document:8f1294f7e46937438027b3cfe480ffb2c6ed0135bd93cc79e537c23f01fedff9","identity_scope":"source_document_reference","source_type":"sec_filing","title":"INO DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07T00:00:00+00:00","retrieved_at":"2026-05-16T04:00:44.817535+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-07T00:00:00+00:00","effective_from":"2026-04-07","effective_until":null,"observed_at":"2026-10-17T04:46:51.162298+00:00","reviewed_at":"2026-10-17T04:46:51.162298+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:14","subject_id":"alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:laurent-m-humeau-ph-d","object_label":"Laurent M. Humeau, Ph.D.","object_source_name_forms":[],"value":"Laurent M. Humeau, Ph.D.: Chief Scientific Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:laurent-m-humeau-ph-d","name":"Laurent M. Humeau, Ph.D."},"title":"Chief Scientific Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-07","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-07","valid_to":null,"recorded_at":"2026-10-17T04:46:51.162298+00:00","sources":[{"id":"alpha:projection-evidence:document:4b6e35f2d5f0e990b07174a46dcbe4b9422ef8f6ae83cd57bc85bb1eca11cb36","identity_scope":"source_document_reference","source_type":"sec_filing","title":"INO DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07T00:00:00+00:00","retrieved_at":"2026-05-16T04:00:45.873098+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-07T00:00:00+00:00","effective_from":"2026-04-07","effective_until":null,"observed_at":"2026-10-17T04:46:51.162298+00:00","reviewed_at":"2026-10-17T04:46:51.162298+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:15","subject_id":"alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:michael-sumner-m-d","object_label":"Michael Sumner, M.D.","object_source_name_forms":[],"value":"Michael Sumner, M.D.: Chief Medical Officer and Head of Development","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:michael-sumner-m-d","name":"Michael Sumner, M.D."},"title":"Chief Medical Officer and Head of Development","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-07","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-07","valid_to":null,"recorded_at":"2026-10-17T04:46:51.162298+00:00","sources":[{"id":"alpha:projection-evidence:document:5a31bde93476f8a37d8a1cb66aac2b1b2e3aa3a1855d7f789b5dcbbd6d35fe90","identity_scope":"source_document_reference","source_type":"sec_filing","title":"INO DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07T00:00:00+00:00","retrieved_at":"2026-05-16T04:00:46.355277+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-07T00:00:00+00:00","effective_from":"2026-04-07","effective_until":null,"observed_at":"2026-10-17T04:46:51.162298+00:00","reviewed_at":"2026-10-17T04:46:51.162298+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65:leadership_role:16","subject_id":"alpha:company:d662c4ff-5dc9-4fb7-9ed0-803f00adcf65","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:peter-d-kies","object_label":"Peter D. Kies","object_source_name_forms":[],"value":"Peter D. Kies: Chief Financial Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:peter-d-kies","name":"Peter D. Kies"},"title":"Chief Financial Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-07","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-07","valid_to":null,"recorded_at":"2026-10-17T04:46:51.162298+00:00","sources":[{"id":"alpha:projection-evidence:document:c24c5ae9b36a12f3ac9677930fba7288f90d4d4134ae372ad980e33a71422925","identity_scope":"source_document_reference","source_type":"sec_filing","title":"INO DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07T00:00:00+00:00","retrieved_at":"2026-05-16T04:00:45.379354+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-07T00:00:00+00:00","effective_from":"2026-04-07","effective_until":null,"observed_at":"2026-10-17T04:46:51.162298+00:00","reviewed_at":"2026-10-17T04:46:51.162298+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"}],"evidence":[{"id":"alpha:projection-evidence:document:f0eccfac42a84b83b40139af5dcc794fe37648530c785fbdb8d50ae0be6e2588","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"INOVIO PHARMACEUTICALS, INC. DEF 14A 2026-04-07","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07","retrieved_at":"2026-04-24T23:51:00.991+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:8f1294f7e46937438027b3cfe480ffb2c6ed0135bd93cc79e537c23f01fedff9","identity_scope":"source_document_reference","source_type":"sec_filing","title":"INO DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07T00:00:00+00:00","retrieved_at":"2026-05-16T04:00:44.817535+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:4b6e35f2d5f0e990b07174a46dcbe4b9422ef8f6ae83cd57bc85bb1eca11cb36","identity_scope":"source_document_reference","source_type":"sec_filing","title":"INO DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07T00:00:00+00:00","retrieved_at":"2026-05-16T04:00:45.873098+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:5a31bde93476f8a37d8a1cb66aac2b1b2e3aa3a1855d7f789b5dcbbd6d35fe90","identity_scope":"source_document_reference","source_type":"sec_filing","title":"INO DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07T00:00:00+00:00","retrieved_at":"2026-05-16T04:00:46.355277+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:c24c5ae9b36a12f3ac9677930fba7288f90d4d4134ae372ad980e33a71422925","identity_scope":"source_document_reference","source_type":"sec_filing","title":"INO DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000011/ino-20260407.htm","source_date":"2026-04-07T00:00:00+00:00","retrieved_at":"2026-05-16T04:00:45.379354+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"coverage_state":"PUBLISHED","quality":{"schema_version":"alpha-record-quality-v2","overall":0.84,"status":"strong","publication_readiness":"ready","dimensions":{"identity":1,"coverage":0.5,"freshness":1,"evidence_completeness":1,"source_authority":0.907,"cross_source_agreement":0.75,"temporal_completeness":0.571},"diagnostics":{"published_claims":28,"factual_claims":28,"claims_with_linked_evidence":28,"disputed_claims":0,"conflicts":0,"stale_claims":0,"stale_claim_ids":[],"temporal_claims":21,"temporal_claims_with_valid_from":12,"missing_coverage_sections":["governance","financials","workforce","ownership","ratings"],"missing_expected_claims":["headquarters","official_website","financial_metric","governance_document","ownership","auditor","legal_matter","risk","ai_governance"]},"derivation":"deterministic_record_projection"},"publication":{"state":"PUBLISHED","published_at":"2026-10-17T04:46:51.162298+00:00","observed_at":"2026-10-17T04:46:51.162298+00:00","reviewed_at":"2026-10-17T04:46:51.162298+00:00","verified_at":"2026-10-17T04:46:51.162298+00:00"},"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":28,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed.","facets":[{"facet":"identity","state":"unclaimed"},{"facet":"evidence","state":"source_reported"},{"facet":"evaluation","state":"not_evaluated"},{"facet":"monitoring","state":null},{"facet":"authority","state":null},{"facet":"freshness","state":"current"}]},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"},"resource":{"uri":"alpha://company/inovio-pharmaceuticals-inc/events","section":"events","href":"https://registry.alpha.ac/api/public/companies/inovio-pharmaceuticals-inc?format=record&section=events","media_type":"application/json","availability":"contract"},"limitations":["Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."]}